Laura Airas
Professor of Neuroimmunology, MD, PhD
laura.airas@utu.fi Itäinen Pitkäkatu 4 Turku |
Neurology; Neuroimmunology; Multiple sclerosis; PET-imaging; MRI; Drug development
Multiple sclerosis research, @multiplesclerosisresearchfinland, Neuroinflammation research, INFLAMES Flagship
Laura Airas is an internationally recognized expert in multiple sclerosis (MS) and has served as Professor of Neuroimmunology at the University of Turku since 2017. She also practices clinically as a neurologist at Turku University Hospital, specializing in the care of MS patients.
Professor Airas earned her MD from the University of Turku in 1991 and completed her PhD in immunology and cell biology under Professor Sirpa Jalkanen. Her dissertation was recognized with a special distinction from the University of Turku. She became a specialist in neurology in 2001 and was appointed Associate Professor (docent) in 2007.
Her international experience includes serving as a Visiting Professor at Yale University in 2016–2017. In 2015, she was awarded the prestigious Grant for Multiple Sclerosis Innovation (GMSI).
Professor Airas is a respected member of the international scientific community. She serves as a reviewer for major neurology and neuroimmunology journals and funding agencies, and is a frequent invited speaker at national and international scientific events.
Professor Airas leads a translational and patient-centered research group focusing on the pathophysiology of progressive MS and the development of novel therapeutic strategies. Her research integrates cutting-edge imaging techniques (PET and MRI), biomarker discovery, and genetic analysis to investigate the role of glial cells in brain neurodegeneration.
Her multidisciplinary group of about 20 members includes physicians, biomedical scientists, biosiatisticians, and students. They collaborate widely with national and international partners in PET imaging, immunology, drug development, and neuroscience.
The research is funded by:
- Research Council of Finland
- State Research Funding (VTR)
- Jane and Aatos Erkko Foundation
- U.S.-based organizations including the U.S. Department of Defense, National MS Society, and the Progressive MS Alliance
The group is a member of the InFLAMES Flagship at the University of Turku, where Professor Airas also serves on the leadership team.
In addition to her academic work, Professor Airas has been the Principal Investigator in numerous international multicenter clinical trials. She currently leads two investigator-initiated trials targeting microglial activation to slow down progression of MS.
Professor Laura Airas is actively engaged in teaching at the University of Turku. She lectures in neurology and neuroimmunology for students in the medical and biomedical degree programmes and trains specialist physicians in neurology.
Her teaching approach emphasizes patient-centeredness, integration of clinical care and research, and the application of up-to-date scientific knowledge. She brings insights from the latest breakthroughs in neuroimmunology and clinical trial methodology directly into the classroom.
Professor Airas also supervises PhD candidates and has served as the primary supervisor for several completed doctoral theses. In addition, she contributes to postgraduate education programmes for neurology specialists and neuroscience professionals. She is a sought-after lecturer at both national and international medical education events.
- Adenosine A2A receptor availability in patients with early- and moderate-stage Parkinson’s disease (2023)
- Journal of Neurology
- Association of serum neurofilament light with microglial activation in multiple sclerosis (2023)
- Journal of Neurology, Neurosurgery and Psychiatry
- Diagnosis and treatment of progressive multiple sclerosis: A position paper (2023)
- European Journal of Neurology
- Early prognosticators of later TSPO-PET-measurable microglial activation in multiple sclerosis (2023)
- Multiple Sclerosis and Related Disorders
- Longitudinal stability of progression-related microglial activity during teriflunomide treatment in patients with multiple sclerosis (2023)
- European Journal of Neurology
- Lymen borrelioosi: suositus diagnostiikasta ja hoidosta (2023)
- Lääkärilehti
- Neuroimaging to monitor worsening of multiple sclerosis : advances supported by the grant for multiple sclerosis innovation (2023)
- Frontiers in Neurology
- PET-measurable innate immune cell activation reduction in chronic active lesions in PPMS brain after rituximab treatment: a case report (2023)
- Journal of Neurology
- TSPO-Detectable Chronic Active Lesions Predict Disease Progression in Multiple Sclerosis (2023)
- Neurology, Neuroimmunology and Neuroinflammation
- Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in (2022)
- Frontiers in immunology
- Association between microglial activation and serum kynurenine pathway metabolites in multiple sclerosis patients (2022)
- Multiple Sclerosis and Related Disorders
- CANVAS - tasapainovaikeuksien ja kroonisen yskän mahdollinen aiheuttaja (2022)
- Duodecim
- Dimethyl fumarate decreases short-term but not long-term inflammation in a focal EAE model of neuroinflammation (2022)
- EJNMMI Research
- Epstein-Barrin virus MS-taudin ajurina (2022)
- Duodecim
- Establishment of a human induced pluripotent stem cell line (TAUi008-A) derived from a multiple sclerosis patient (2022)
- Stem Cell Research
- Innate Immune Cell-Related Pathology in the Thalamus Signals a Risk for Disability Progression in Multiple Sclerosis (2022)
- Neurology, Neuroimmunology and Neuroinflammation
- Microglia in multiple sclerosis - Pathogenesis and imaging (2022)
- Current Opinion in Neurology
- MS-taudin varhainen ja tehokas hoito kannattaa (2022)
- Erikoislääkäri
- Phenotyping of multiple sclerosis lesions according to innate immune cell activation using TSPO-PET (2022)
- Brain Communications
- Raskauden vaikutukset soluvälitteisiin autoimmuunitauteihin - erityisesti MS-tautiin (2022)
- Duodecim